skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Management of hypoactive sexual desire disorder in women: current and emerging therapies

Review

(2937) Views  (957) Full article downloads

Authors: Rossella E Nappi, Ellis Martini, Erica Terreno, et al

Published Date July 2010 Volume 2010:2 Pages 167 - 175
DOI: http://dx.doi.org/10.2147/IJWH.S7578

Rossella E Nappi1,2, Ellis Martini1,2, Erica Terreno1,2, Francesca , Albani2, Valentina Santamaria1,2, Silvia Tonani MD1,2, Luca Chiovato MD2, Franco Polatti MD1

1Research Center for Reproductive Medicine, Section of Obstetrics and Gynecology, Department of Morphological, Eidological and Clinical Sciences, 2Gynecological Endocrinology and Menopause Unit, Department of Internal Medicine and Endocrinology, IRCCS Maugeri Foundation; University of Pavia, Italy

Abstract: Hypoactive sexual desire disorder (HSDD) is a common multifactorial condition which is characterized by a decrease in sexual desire that causes marked personal distress and/or interpersonal difficulty. The general idea that HSDD is a sexual dysfunction difficult to treat is due to the large number of potential causes and contributing factors. Indeed, a balanced approach comprising both biological and psycho-relational factors is mandatory for accurate diagnosis and tailored management in clinical practice. There are currently no approved pharmacological treatments for premenopausal women with HSDD, while transdermal testosterone is approved in Europe for postmenopausal women who experience HSDD as a result of a bilateral oophorectomy. Even though the role of sex hormones in modulating the sexual response during the entire reproductive life span of women is crucial, a better understanding of the neurobiological basis of sexual desire supports the idea that selective psychoactive agents may be proposed as nonhormonal treatments to restore the balance between excitatory and inhibitory stimuli leading to a normal sexual response cycle. We conclude that the ideal clinical approach to HSDD remains to be established in term of efficacy and safety, and further research is needed to develop specific hormonal and nonhormonal pharmacotherapies for individualized care in women.

Keywords: sexual desire, distress, testosterone, psychoactive drugs, psychosexual interventions

Erratum for this paper has been published






 

Other articles by Dr R E Nappi



Readers of this article also read:

Safety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausal vasomotor symptoms: a review
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
The role of transdermal estrogen sprays and estradiol topical emulsion in the management of menopause-associated vasomotor symptoms
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Methemoglobinemia due to topical pharyngeal anesthesia during endoscopic procedures
Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Antibacterial treatment of bacterial vaginosis: current and emerging therapies
Transvaginal sonographic evaluation at different menstrual cycle phases in diagnosis of uterine lesions
Effect of a hormone-releasing intrauterine system (Mirena®) on aromatase and Cox-2 expression in patients with adenomyosis submitted or not, to endometrial resection